News News Details

Dual Catalogues Released Together: Newly Added Varieties from Three Yifeng-Portfolio Innovative Drug Companies Included

Date: 2026-11-16
Views: 2


On November 14, the 2026 Innovative Drug High-Quality Development Conference, jointly guided by the National Healthcare Security Administration and the Jiangsu Provincial People's Government, was held in Suzhou, with nearly 880 institutions and 1,500 industry representatives in attendance.

At the conference, the National Healthcare Security Administration released the "2026 Edition National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue" and the "2026 Edition Commercial Health Insurance Innovative Drug Catalogue," and provided a detailed introduction to the catalogue adjustments.

The commercial health insurance catalogue is an institutional innovation in the development of China's multi-tiered medical security system. It is an important instrument for further clarifying the boundaries of basic medical insurance coverage and promoting the differentiated and complementary development of basic medical insurance and commercial health insurance. It focuses on including drugs with significant clinical value, a high degree of innovation, and clear patient benefits that fall beyond the scope of basic medical insurance coverage.

Specifically, in this round of adjustments to the commercial health insurance catalogue, 12 innovative drugs from 11 companies were newly included, bringing the total number of drugs in the commercial health insurance catalogue to 28. This further enriches the supply of products in frontier fields such as cell and gene therapy, rare diseases, and oncology.

In this round of adjustments to the basic medical insurance catalogue, a total of 107 drugs were newly added, and 34 varieties with no clinical supply or that can be better replaced were removed. After the adjustment, the total number of drugs in the catalogue increased to 3,331, including 1,935 Western medicines and 1,396 traditional Chinese patent medicines. The new edition of the catalogue will officially take effect on January 1, 2027.

Notably, products from Changtai Pharmaceutical, Healthgen Biotechnology, and Ascentage Pharma—three companies in which Efung Capital has invested—were successfully included as newly added varieties in the 2026 National Basic Medical Insurance Drug Catalogue. The inclusion of these three companies' innovative drug products in the national medical insurance catalogue marks authoritative recognition of their clinical value, innovation, and accessibility, and will further enhance patient access to the relevant innovative therapies, enabling more patients to access and afford high-quality innovative drugs.

With the implementation of the new edition of the basic medical insurance catalogue and the commercial health insurance innovative drug catalogue, the multi-tiered protection system for innovative drugs will become more complete, and the innovative drug industry is expected to embrace broader development space.

[Disclaimer]

The content of this article represents only the views of the Company based on currently available public information and materials provided by portfolio companies. It does not constitute any investment advice, medical advice, or guarantee of the performance of any specific company. Investment involves risks, and caution is advised when entering the market. Readers should make independent judgments based on public information. Unauthorized reproduction or use for commercial purposes is prohibited.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务